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Abstract: 
Introduction: Cancer stems from mutations in specific genes that induce uncontrolled cell proliferation. Dendritic cells (DCs) are 
important immunologic cells and play a crucial role in the induction of an antitumour response.
Patients and methods: We examined the immune response mediated by T lymphocytes, helper T cells, cytotoxic T cells, and regulatory 
T cells, as well as the cytokines [interleukin (IL)-2, IL-12, interferon (IFN)-γ, tumour necrosis factor (TNF)-α and IL-10], produced by 
these cell populations, in cancer patients (N = 7) undergoing immunotheraphy with autologous DCs.
Results: We observed an initial increase in T helper cells (CD4+) expressing IL-2, IFN-γ, IL-12, TNF-α, and IL-10 after initia-
tion of treatment, with statistically significant for the cytokines IL-2, TNF-α and IL-10. A similar significant effect was observed 
for IL-2-  expressing cytotoxic T cells (CD8+). The percentage of total T cells (CD3+) remained elevated throughout immunotherapy. 
  Regulatory T cells (CD25+/FOXP3+) only showed high percentage of their maximum value when analyzed the pretreatment levels, 
with statistically significant.
Conclusion: Immunotherapy with DCs stimulated the immune response, as evidenced by an increase in percent fluorescence of most 
cell populations investigated during the specified treatment period.
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Introduction
Cancer represents a set of genetic diseases caused by 
several mutations in specific genes, leading to genomic 
instability and consequently to accelerated and uncon-
trolled cell proliferation.1 The changes occurring in 
cancerous cells culminate in the production of “dan-
ger signals” resulting in the expression of altered pro-
teins that can be recognized as foreign to the immune 
system, generating an antitumour response.2
The immune system consists of two main lines of 
response: innate immunity and adaptive or acquired 
immunity. Innate immunity is composed of cells such 
as macrophages, dendritic cells (DCs), natural killer 
(NK) cells, neutrophils, basophils, eosinophils, and 
mast cells, which can be characterized by their rela-
tively fast response, however, with absence of induc-
tion of immunologic memory.3,4
Stimulation of the innate immune response leads 
to  activation  of  acquired  immunity,  composed  of 
cytotoxic T cells (CD8+), T helper cells (CD4+), and 
B cells. These cells are characterized by presenting a 
wide variety of antigen receptors and their ability to 
generate immunologic memory.3,5
DCs  are  considered  to  be  the  most  important 
antigen-presenting cell. Through a cross-presentation 
mechanism, they can activate cytotoxic T lympho-
cytes (CD8+) as well as T helper cells (CD4+), with T 
helper cells being critical in the production of cytok-
ines involved in acquired immunity.6–8
Although the main focus of studies involving the 
antitumour immune response have been aimed mainly 
at cytotoxic T lymphocytes, there have been reports 
that T helper cells (CD4+) can also exhibit a wide 
range of functions in this type of immune response. 
Some epitopes derived from human tumour antigens 
recognized by human CD4+ T cells have already been 
described.9,10
Tumour  cells  can  also  suppress  DC  function, 
thereby  causing  them  to  be  incapable  of  stimulat-
ing and activating T cells efficiently.11,12 Given the 
importance of these cells, clinical studies related to 
immunotherapy involving DCs have been performed 
for various tumour types, with noteworthy results13–15 
and it was shown that the vaccine was generally well 
tolerated without significant adverse effects. Hence, 
immune responses elicited by immunotherapy with 
DCs have been observed.
Therefore, given the complexity of inducing an 
antitumour response, it is critical that we improve 
our understanding of immune cell behaviour, particu-
larly T lymphocytes, so that possible immunological 
mechanisms responsible for tumour regression can be 
inferred. Furthermore, such research can enable the 
development of new and effective immunotherapeu-
tic protocols for the treatment of cancer.
This study aimed to elucidate the immune response 
of T lymphocytes in cancer patients during immuno-
therapy with autologous DCs. For this purpose, we 
evaluated peripheral blood samples from the patients 
before and during immunotherapy for total T lympho-
cytes, T helper cells, cytotoxic T cells, and the cytokines 
produced by them [interleukin (IL)-2, IL-12, interferon 
(IFN)-γ, tumour necrosis factor (TNF)-α, and IL-10. 
We  also  assessed  levels  of  the  transcription  factor 
FOXP3 and the cell surface marker CD25, which is 
essential for identification of regulatory T cells.
Methods
Patients
Seven female patients diagnosed with cancer were 
selected  at  the  Research  Institute  for  Oncology 
(IPON)/Discipline of Gynecology and Obstetrics at 
UFTM. All individuals involved were fully informed 
about the intentions of the research study and signed 
a consent form to confirm their participation (case 
number 683-2006), in accordance with the research 
ethics committee requirements.
Some of the participating patients had previously 
been treated with conventional methods, such as che-
motherapy and/or radiation therapy. As such, in order 
to participate in the current study and undergo immu-
notherapy with DCs, such patients were required to 
wait at least 2 months prior to starting the new treat-
ment. Table 1 shows a summary of the general char-
acteristics for each patient participating in the study.
Acquisition of mononuclear cells
Mononuclear  cells  were  obtained  from  peripheral 
blood samples from the patients recruited to partici-
pate in the study. The mononuclear cells were isolated 
from peripheral blood cells by density gradient and 
centrifugation in  Ficoll-Hypaque  (BD    Biosciences) 
solution.  The  cells  were  re-suspended  in  15  ml 
of  IMDM,  enriched  with  5%  fetal  bovine  serum, T lymphocytes in cancer treatment using immunotherapy with DCs
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1% penicillin/streptomycin, and 1% gentamicin. Cel-
lular viability was assessed using Trypan blue. All 
procedures were conducted under sterile conditions.
DC vaccines
Mononuclear  cell  cultures  were  maintained  in 
vitro at 37 °C and 5% CO2 for 7 days in GM-CSF 
and IL-4 to support DC differentiation. The tumor 
  antigens were obtained by tumor biopsy from each 
patient. The neoplastic cells were lysed by cycles of 
freezing and used at a concentration of 100 ug/ml. 
  Differentiated  cells  were  placed  in  contact  with 
tumour  antigens,  obtained  from  each  patient,  and 
subjected  to    electroporation.  DCs  activated  with 
tumour antigens were infused by subcutaneous injec-
tion into the forearm (5∼10 × 106 cells   autologous 
DCs/patient) and the procedure was repeated at a 
mean interval of 15 days.
Flow cytometry
Over the course of the study, peripheral blood samples 
were drawn from the patients and cells were evaluated 
by flow cytometry (BD FACS Calibur cytometer and 
cell sorter). Cytometry protocols were deployed in 
accordance with those suggested by the manufacturer 
(BD Biosciences). The peripheral blood cells were 
collected for the following markers in all patients: 
total T (CD3+), helper T (CD4+), cytotoxic T cells 
(CD8+), and regulatory T cells (CD25+/FOXP3+). 
The procedure was performed prior to initiating ther-
apy  with  DCs  (pre-treatment  analysis)  and  further 
analysis was performed every 15 days.
Leukocytes were isolated from peripheral blood 
samples via centrifugation at 4 °C using a standard 
cell  lysing  protocol  (BD  Biosciences—FACSTM 
Lysing Solution), in accordance with manufacturer’s 
instructions.
For T cell tagging, initially cells were re-suspended 
in PBS for extracellular tagging. For tagging, α-CD3 
PE antibodies were used for total T cells, α-CD4 PE 
for T helper cells, α-CD8 PE for cytotoxic T cells, 
and α-CD25 PE for regulatory T cells. After extracel-
lular tagging was completed, cells were incubated at 
4 °C for 30 min, and then rinsed twice by centrifuga-
tion with PBS.
Following the rinses, a fixation and permeabiliza-
tion  solution  was  added  (BD  Cytofix/CytopermTM) 
for duration of 20 min at 4 °C. The cells were rinsed 
twice again with Perm/wash (BD Biosciences) buffer 
prior to the second tagging. For intracellular tagging 
α-IL-2 FITC antibodies were utilized for cytotoxic 
T cells and T helper cells. T helper cells were also 
tagged with α-IL-12 FITC, α-IL-10 FITC, α-IFN-γ 
FITC  and  α-TNF-α  FITC  antibodies.  α-FOXP3 
FITC antibodies were used to tag regulatory T cells. 
Following intracellular tagging, cells were incubated 
once more at 4 °C for a 30 min duration. Finally, cells 
were re-suspended in 500 µL of PBS for cytometric 
analysis using BD FACSCalibur™. For an accurate 
determination of the cells, corresponds to lympho-
cytes and not other cell types, we determine the region 
to be analysed by constructing a gate according to a 
chart control for relative size (Forward Scatter FSC) 
and granularity and complexity (Side Scatter SSC) 
Table 1. Patient characteristics based on age, tumour type, stage, and previous treatments.
patient Age (years) Tumour type stage (TnM)* previous treatments
1 76 Vaginal cancer IIIB (T3n1M0) –
2 77 Vaginal melanoma IIC (T4nxMx) –
3 48 Vaginal cancer 0 (tumour in situ) radiation therapy,  
surgery, IFn
4 66 Breast cancer IV (T4dn2M1) Chemotherapy, radiation   
therapy, surgery.
5 39 Cervical cancer IVB (T2bn0M1) –
6 80 Breast cancer IIIC (T4dn3Mx) Chemotherapy, radiation   
therapy, surgery.
7 27 Breast cancer IV (T2n1M1) Chemotherapy, radiation   
therapy, surgery.
notes: *TnM = classification of cancer staging, where T refers to the size of the tumour, N refers to any involved lymph nodes, and M refers to the 
presence of metastasis.rodrigues et al
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in each experiment and for each patient. Figure 1 is 
an illustrative example of how the determination was 
performed by flow cytometry data.
Statistical analysis
The data are shown as median values, with error bars 
representing the range from the minimum value (lower 
bar) to the maximum value (upper bar). The results 
were analyzed using the Kruskal-Wallis nonparamet-
ric test (ANOVA). Statistical analysis and graphing 
were performed using GraphPad Prism version 5.0 
(GraphPad Software, Inc.). Results were considered 
statistically significant at P , 0.05.
Results
Safety and toxicity of the vaccine
Immunotherapy  with  DCs  was  shown  to  be  safe 
without any significant side effects or toxicity. Only 
patient 2, who was in treatment for metastatic vaginal 
melanoma showed worsening of a pre-existing condi-
tion (vitiligo) after commencing treatment. However, it 
was not possible to determine whether this worsening 
occurred as a result of the action of the vaccine or as a 
result of systemic activation of an immune response.
Cell population analysis using flow 
cytometry
A high percentage of T lymphocytes (.60%) were 
observed to be CD3+ (fluorescently labelled) in the pre-
treatment analysis and that percentage increased fol-
lowing initiation of treatment until the twelfth analysis, 
after which a rapid reduction of fluorescent labelling 
was observed (P = 0.3986). This finding is contrary to 
the results observed for the other cell types   investigated 
as  CD4+,  CD8+  and  CD25+FOXP3+  (described 
below), which fell to nearly to zero (Fig. 2A).
CD4+ and CD8+ T lymphocytes showed similar 
patterns of IL-2 expression, with an initial increase 
in the percentage of fluorescently labelled cells after 
initiation of treatment with DCs. The early increase 
persisted until the seventh and tenth analysis, respec-
tively, and then was followed by a reduction. These 
treatment effects were highly significant for both cell 
populations (P = 0.0044; P = 0.0191, respectively) 
(Fig. 2B and 2C).
CD4+  T  lymphocytes  showed  a  trend  toward 
an increase in percentage of IFN-γ-positive (fluo-
rescent labelled) cells upon initiation of immuno-
therapy, until the seventh analyse and that upward 
trend was followed by a reduction (P = 0.5688) 
(Fig. 3A).
Similar patterns of results were obtained for the 
expression  of TNF-α  and  IL-12  by  CD4+ T  cells 
(Fig. 1), with a rapid initial increase that was signifi-
cant for TNF-α (P = 0.0419) (Fig. 3B), but only a 
weak trend for IL-12 (P = 0.6774) (Fig. 3C). These 
cells exhibited a significant increase in IL-10 expres-
sion, as evidenced by the percentage fluorescent cells, 
after treatment initiation (P = 0.0111), followed by a 
tendency toward reduction after the eighth analysis 
(Fig. 3D).
With regard to the percentage of regulatory T cells 
(CD25+, FOXP3+), no considerable stimulation was 
observed (P = 0.0278) (Fig. 3E).
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Figure 1. A) Flow cytometry of peripheral blood of patient 2. gate 1 (arrow) in lymphocytes. B) shows double labeling CD4+/IL-12+ lymphocytes in gate 1.T lymphocytes in cancer treatment using immunotherapy with DCs
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Discussion and conclusion
In recent years, DCs’ immunogenic potential for immu-
notherapy has been the focus of a multitude of studies. 
The effects of these cells on the host’s   immunity hold 
the key to further development of this work.
The study of immune response in cancer patients is 
difficult to be carried by several factors. The immune 
response is already a complex factor being studied in 
humans because this system is highly dependent on the 
genetics of each individual. The selection of patients 
depends on that all therapies have been used without 
success, the consent of the patient and/or family and a 
good general physical condition. Another point is the 
variation in the levels of cytokines in humans, which 
is very variable, however, likely to demonstrate sta-
tistical significance the examination in some tests.
The immunotherapy using autologous DCs devel-
oped in this study was well tolerated, and no sig-
nificant side effects were observed to the vaccines. 
Only one patient experienced a mild worsening of a 
pre-existing case of vitiligo, which is known to be a 
common autoimmune response against melanocytes 
during treatment of melanoma.16,17
With regards to the population of T helper cells 
(CD4+) expressing IFN-γ, it was observed an increased 
percentage  of  fluorescently  labelled  IFN-γ-positive 
cells, after the start of immunotherapy with DCs. The 
present study also showed that CD4+ T cells do exhibit 
a significant increase in TNF-α expression after stimu-
lation with DC immunotherapy. Similar results have 
been described previously in the literature. Fong et al18 
assessed the effects of DC vaccines via different routes 
of administration (intradermal, intravenous and intra-
lymphatic routes) and detected the production of IFN-γ 
by intradermal and intralymphatic routes. However, 
they found low TNF-α expression levels in 1/6 patients 
treated with an intravenous DC vaccine.18 Mumberg 
et al19 deduced that cytokine IFN-γ plays a central role 
in the elimination of tumour cells by CD4+ T cells, 
however, this effect seemed to be indirect, since the 
tumour cells remained negative for MHC class II mol-
ecules after stimulation with IFN-γ.
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TNF-α is a multifunctional cytokine and a major 
mediator of inflammation. It is involved in cell sur-
vival, proliferation, and apoptosis. It can be detected 
in  stromal  and  malignant  cells  in  several  types  of 
cancer.20 Chronic production of this cytokine in the 
neoplastic  micro-environment  can  induce  tumour 
development and spread. In contrast, TNF-α is also 
important in cell destruction mediated by NK cells 
and CD8+ T cells.21,22 Hence, TNF-α is functionally 
pleiotropic, as it is able to engage in responses that 
are tumour promoting or tumour suppressing depend-
ing on the stimuli received by the cells.
An interesting finding of this work and unpub-
lished in the literature is that we observed a slight 
stimulation of IL-12 expression by CD4+ T lympho-
cytes after the onset of DC immunotherapy. Both 
the  IL-12  and  IFN-γ  cytokines  are  important  for 
stimulation of the Th1 immune response.23 In addi-
tion, the IL-12 induces cytotoxic effects in NK and 
CD8+ cells, aside from stimulating their production 
of IFN-γ.24,25
IL-10,  in  turn,  showed  a  considerable  increase 
after  commencement  of  the  treatment.  IL-10  can 
be  secreted  by  a  variety  of  different  cells,26,27  and 
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Figure 3. Quantification of T helper cell percentage (CD4+) expressing cytokines IFn-γ (A), TnF-α (B), IL-12 (c), and IL-10 (D), and regulatory T cells 
(CD24+FOXP3+) (e), (median, maximum, and minimum values), prior to and during immunotherapy with DCs.T lymphocytes in cancer treatment using immunotherapy with DCs
Clinical Medicine Insights: Oncology 2011:5  113
although it is most often described in terms of its 
immunosuppressive action, there are reports describ-
ing its effector function on CD8+ T cells.28 IL-10, 
generally considered to be a Th2 cytokine, is capable 
of stimulating B cell function. On the other hand, 
there is evidence suggesting that it may be produced 
by Th1 cells,29,30 and that it may also exhibit an anti-
tumour function.31,32
Saraiva et al33 demonstrated that in vitro differen-
tiation of IL-10-expressing Th1 cells was dependent 
upon  the  activation  of  transcription  factor  STAT-
4-induced  by  cytokine  IL-12,  through  a  powerful 
activation via T-cell receptors (TCRs) and phospho-
rylation  of  extracellular-signal-regulated  kinases 
(ERK) 1 and 2. These findings further demonstrate 
the multifunctional role of IL-10 and its dependence 
on IL-12 for its production by Th1 cells.
In  the  current  study,  total T  cells  demonstrated 
elevated expression of the CD3+ marker practically 
throughout the entire period of treatment with DCs. 
Our  assessment  of  IL-2  expression  by  CD4+  and 
CD8+ T cells also yielded similar results for these 
two cell types: an early increase in expression after 
initiation of immunotherapy followed by a decline to 
nearly zero by the end of the analysis.
These findings demonstrate that activation of DCs 
in vitro can enhance immune effector responses in T 
cells upon vaccination, while inducing a significant 
increase in IL-2 expression. IL-2 is considered to be 
an important factor in proliferation of T lymphocytes 
against antigenic stimulation and plays a   central role 
in the regulation of T cells. Furthermore, its expression 
is considered to be indicative of cellular activation.34
Our findings corroborate the literature. In a study in 
which autologous DC vaccination was administered 
to patients with metastatic breast cancer and renal 
cancer, Avigan et al35 observed an increased in the per-
centage of CD4+ and CD8+ T cells that was related 
to increased expression of the cytokine IFN-γ, which 
apparently led to induction of antitumour activity. In 
a study examining advanced stage breast and ovarian 
cancer patients who were vaccinated with autologous 
DCs, Brossart et al36 described observing a specific 
antigenic response in 5/10 patients, as evidenced by 
IFN-γ production by cytotoxic T lymphocytes.
The  tendency  for  there  to  be  a  sharp  reduction 
in IL-2-tagged CD4+ and CD8+ T cells after a cer-
tain time in treatment, despite sustained high levels 
of total T cell marker (CD3+) expression, suggests 
that  there  may  be  another  CD3+  cell  population 
involved. Two cells types can likely be Tγ/δ37–39 and 
NK T-cells.40,41 Both populations are identified as hav-
ing regulatory and protective functions in cancer.42–46 
Thus,   investigating these cell types may help explain 
the reduced immune response that is observed after 
some time of immunotherapeutic stimulation, as well 
as the conservation of marker CD3+.
We  did  not  observe  evidence  of  stimulation  of 
CD25+/FOXP3+ regulatory cells in this study. There 
was only a higher maximum value in the pre-therapy 
analysis, relative to the maximum values observed 
during treatment. Thus, we can conclude that although 
a decrease in immune response was observed vis-à-
vis the assessed markers, which suggests that immu-
nosuppression did occur, these cell types were not 
responsible for the findings.
On  the  contrary,  others  have  demonstrated  an 
induction of regulatory T cells after immunotherapy 
with DCs. According to Berntsen et al,47 significantly 
increased levels of CD4+/CD25+/FOXP3+ Treg cells 
(vs.  pretreatment  levels)  were  found  in  peripheral 
blood samples of patients with metastatic renal car-
cinomas treated with a DC vaccine combined with 
cytokine IL-2.
Our results indicate that there is a stimulation of the 
response of CD4+ T cells expressing IL-2, IFN-γ, and 
TNF-α, as well as of IL-2-expressing CD8+ T cells, sug-
gesting that immunotherapy with DCs has the ability to 
induce a Th1 response. As such, the immune system is 
probably acting as an effector against tumour cells.
In the present study, some of the patients involved 
were treated for a prolonged period of time and given 
the vaccine and immunological stimulation on sev-
eral occasions. One explanation for the diminished 
response over the course of treatment could be due to 
selection for tumour cell variants with immunoresis-
tant phenotypes.48 Additionally, after a certain period 
of vaccination, there could have been a loss in expres-
sion of MHC class I molecules by tumour antigens, 
a  major  mechanism  of  immune  system  evasion.49 
The maturation stage of DCs is also a determining 
  factor for directing a Th1 response, as immature DCs 
secrete IL-10 leading to a Th2 response.50,51 As such, 
it is important to continuously review the therapeutic 
protocol being used and to seek innovative strategies 
to prevent the development of new tumour escape rodrigues et al
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mechanisms  in  order  to  maintain  a  good  response 
during the treatment period.
It should be noted that the present study was based 
on  the  analysis  of  the  percentage  of  fluorescently 
labelled cells for each assessed marker, and that the 
analysis  of  fluorescence  intensity  was  important. 
Thus, although there may be a numerical decline in 
tagged cells after a certain period of treatment, it is 
possible that there could still have been an increase in 
the numbers of assessed markers. In other words, even 
though there may be a smaller number of cells, each 
cell might be expressing a larger number of surface 
markers or producing a larger quantity of cytokines. 
Given the important implications of this possibility, 
follow up studies are already underway.
In  conclusion,  upon  assessing  immunologic 
response before and during treatment, we observed 
that immunotherapy with DCs was capable of stim-
ulating the immune system in cancer patients. This 
finding was evidenced by observations of increased 
percentages fluorescently labelled cells for markers 
of the major cell populations studied.
Upon  immunotherapeutic  intervention  with  DCs, 
activated in vitro and pulsed with tumour specific anti-
gens for each patient, an increase in the percent fluores-
cently labelled cells was observed for the majority of 
cell populations assessed. The increases were particu-
larly significant for T helper cells expressing TNF-α, 
IL-2, IL-10, and for cytotoxic T cells expressing IL-2. 
The findings of this study indicate that after a certain 
period of immunologic stimulation against tumour anti-
gens, there is a reduction in the immunologic response.
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